Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia, B-cell lymphoma, non-Hodgkin lymphoma and multiple myeloma. Despite reporting high response rates, the use of CAR-T therapy is associated with a number of practical challenges, including treatment-related adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as high costs and manufacturing difficulties. It is thus crucial to reduce the incidence and optimize the management of toxicities through careful patient selection and monitoring. CAR-T therapy is also being explored as a treatment option for chronic lymphocytic leukemia (CLL), where attempts with CAR-T have been unsuccessful due to CLL-induced T-cell dysfunction, a process that is currently not well understood.
In this podcast, Arnon Nagler, MD, MSc, of the Chaim Sheba Medical Center, Tel-Hashomer, Israel, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Barcelona, Spain, Christian Chabannon, MD, PhD, of the Institut Paoli Calmettes, Marseille, France, and Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discuss key considerations for the use of CAR-T therapy in clinical practice, as presented at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH) 2021.
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
Novel developments in lower-risk MDS & important practical considerations when treating patients
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.